Medtronic Gets Extra FDA Attention To Hasten Approval Of Next-Gen Insulin Pump
This article was originally published in The Gray Sheet
Executive Summary
CDRH has formed a close working partnership with Medtronic to facilitate quick approval for a next-generation insulation pump-glucose monitor, offering an illustration of what the center’s future plans might be for addressing devices with breakthrough potential.
You may also be interested in...
US FDA Approves First 'Artificial Pancreas' In Medtronic's MiniMed 670G
The hybrid closed-loop automated insulin delivery system, the first closed-loop system approved anywhere in the world, automatically monitors glucose and provides appropriate basal insulin doses in people with type 1 diabetes.
Medtronic Launches U.S. Trial For Predictive Glucose Monitor-Pump System
The single-arm pivotal trial is assessing the firm's next-generation diabetes system, which adds predictive algorithm features and a smaller sensor compared to the currently marketed MiniMed 530G low-glucose suspend device, marking another step towards an artificial pancreas, Medtronic says.
Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway
The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential payoff to patients is large enough and postmarket controls are sufficient.